Biomarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Report - Results, Call & Slides
BioMarin Pharmaceutical (BMRN) reported strong Q2 2025 earnings, beating analyst expectations for both EPS and revenue. The company recorded an actual EPS of $1.23 against a consensus of $0.86, and actual revenue of $827.47 million, surpassing the expected $761.95 million. This represents a significant …